To the best of our knowledge, this case report is the first describing an enteric-type lung adenocarcinoma with diffuse skin lesions and a BRAF p.V600E mutation, undergone to a histologically confirmed complete cutaneous response to dabrafenib and trametinib. The gene discussed is BRAF; the disease is lung adenocarcinoma.